Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib vs Osimertinib in EGFR-mutated NSCLC (TREBLE)
NCT05493501Phase 3Terminated
- Sponsor
- EQRx
- Start
- Dec 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of almonertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by EQRx. Primary endpoint: Progression Free Survival up to 5 years. Started Dec 2022; status: terminated.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05493501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493501.